Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

nder)20112010

2010

2011

2010

2010Zyprexa®

$1,182.3$1,212.7(3)%$3,872.4$3,690.65%Cymbalta®

1,068.6825.329%2,980.82,496.219%Alimta

629.7560.312%1,823.01,639.511%Humalog®

593.2494.020%1,705.51,505.113%Cialis

469.8406.516%1,381.41,233.512%Humulin®

301.5278.08%903.2801.013%Evista®

270.1256.85%799.7757.96%Forteo®

240.3199.720%687.3603.814%Strattera

153.2127.920%449.5421.37%Gemzar

91.0324.6(72)%359.5905.8(60)%Animal Health

451.0353.228%1,210.4967.025%Total Revenue

$6,147.9$5,654.89%$18,239.9$16,889.08%Zyprexa

In the third quarter of 2011, Zyprexa sales totaled $1.182 billion, a decrease of 3 percent compared with the third quarter of 2010.  U.S. sales of Zyprexa decreased 7 percent to $563.2 million, driven by lower volume, partially offset by higher net effective selling prices. Zyprexa sales in international markets increased 2 percent, to $619.1 million, driven primarily by the favorable impact of foreign exchange rates, partially offset by lower prices and lower volume. The company lost patent exclusivity for Zyprexa in most of Europe in September 2011 and will lose exclusivity in the U.S. on October 23, 2011. While it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales, the company expects the introduction of generics to result in a rapid and severe decline in Zyprexa sales.  

Cymbalta

For the third quarter of 2011, Cymbalta generated $1.069 billion in revenue, an increase of 29 percent compared with the third quarter of 2010. U.S. sales of Cymbalta increased 26 percent, to $809.5 million, driven by increased prices and higher demand. Revenue outside the U.S. was $259.1 million, an increase of 42 percent, driven primarily by higher demand in international markets and, to a lesser extent, the favorable impact of foreign exchange rates.

Alimta

For the
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... The Prix Galien USA committee recognized excellence in scientific ... during the fifth annual Prix Galien Awards Gala. The Pro ... for best biotechnology product and best pharmaceutical agent were presented ... in New York City.   The Prix Galien ...
... AdvaMed 2011: The MedTech Conference ... exhibitors including Abbott, Abiomed, B. Braun Medical, Baxter ... KCI, and MIT MEDRC in Innovation Alley, a ... technologies. Three sector meet-ups focused on orthopedic, wound ...
Cached Medicine Technology:Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony 2AdvaMed 2011: The MedTech Conference Closing Day Features Life Changing Innovation, Policymaker Addresses 2
(Date:7/12/2014)... Angeles, CA (PRWEB) July 12, 2014 ... buyer power score of 4.1 out of 5. ... market that have been underpinning buyer negotiation power ... IBISWorld procurement analyst Anna Son, “during the period, ... with rising costs associated with new product development, ...
(Date:7/11/2014)... 12, 2014 Recently, MagicQuinceaneraDresses.com, the popular ... new collection of 2014 Quinceanera dresses . The ... want to look fashionable without paying a large amount ... up to 57% off. , The company’s online shop ... get amazing special occasion outfits. In addition to exquisite ...
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
(Date:7/11/2014)... 2014 As part of its ... LLP has been closely monitoring the ongoing meeting ... Obstetrics and Gynecology Devices Panel, which has ... cancer risks associated with the use of power ... a report published by Dow Jones Business News, ...
Breaking Medicine News(10 mins):Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... So what do you get for the nut,that has ... the Ask Doctor Chuck talking therapy doll?, You can ... by providing,someone who needs it, their own personal and portable ... kook in line, which could,earn you the undying gratitude of ...
... Higher-risk Myelodysplastic Syndromes (MDS), Thalidomide in Multiple ... ... Pharmion Corporation,(Nasdaq: PHRM ) reported today that data from ... will,be presented at the American Society of Hematology,s (ASH) 49th Annual,Meeting ...
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... More in ... 2008, - Late-Stage Pipeline Offers Promising Outlook; 6 Launches Expected by end ... of 2011, ... in Unprecedented 44 New Molecules Under Development, - Transformation Efforts to Focus ...
... StemCor Systems, Inc., a,medical device company developing ... it has acquired U.S. Patent 6,849,051,"Devices And ... associated,know-how from USPure Sciences, LLC. The patent ... from bone cavities. The concept and,technologies are ...
... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) today ... a company overview at the New York Society,of ... Pharma,Conference on December 12, 2007 at 4:05 p.m. ... NYSSA,s headquarters at 1177 Avenue of the Americas ...
Cached Medicine News:Health News:The Cure for Holiday Stress 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 3Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 4Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 5Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 6Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 7Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 8Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 9Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 10Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 3Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 4Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 5Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 6Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 7Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 8Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 9Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 10Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 11Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 12Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 13Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 14Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 2Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 3Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 2Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 3
Alkaline phosphatase FS (DGKC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Medicine Products: